Captrust Financial Advisors Raises Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

Captrust Financial Advisors boosted its stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 32.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,539 shares of the company’s stock after purchasing an additional 4,513 shares during the quarter. Captrust Financial Advisors’ holdings in scPharmaceuticals were worth $85,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of SCPH. Assenagon Asset Management S.A. increased its holdings in scPharmaceuticals by 266.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after purchasing an additional 52,870 shares during the period. Bank of New York Mellon Corp increased its holdings in scPharmaceuticals by 15.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock worth $375,000 after purchasing an additional 11,269 shares during the period. Balanced Rock Investment Advisors LLC increased its holdings in shares of scPharmaceuticals by 10.3% in the 2nd quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company’s stock valued at $275,000 after acquiring an additional 5,882 shares during the last quarter. AIGH Capital Management LLC increased its holdings in shares of scPharmaceuticals by 3.4% in the 2nd quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock valued at $15,244,000 after acquiring an additional 115,206 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its holdings in shares of scPharmaceuticals by 76.9% in the 2nd quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock valued at $2,163,000 after acquiring an additional 216,122 shares during the last quarter. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Trading Up 0.3 %

NASDAQ:SCPH opened at $3.20 on Tuesday. The stock’s 50 day moving average price is $3.88 and its 200 day moving average price is $4.36. The company has a market capitalization of $160.13 million, a PE ratio of -1.68 and a beta of 0.14. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. scPharmaceuticals Inc. has a 52-week low of $3.08 and a 52-week high of $6.71.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a report on Thursday, November 14th. Craig Hallum dropped their price objective on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.